GALT
Galectin Therapeutics Inc
NASDAQ: GALT · HEALTHCARE · BIOTECHNOLOGY
$3.93
+0.77% today
Updated 2026-09-28
Market cap
$393.31M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.43
Dividend yield
—
52W range
$2 – $7
Volume
0.3M
WallStSmart proprietary scores
19
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.5
Quality
C3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-34.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →261 stocks currently score above 75
Price targets
Analyst target
$11.00
+179.90%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity -1.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -34.27 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.44M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-38.78M | $-41.07M | $-47.05M | $-30.84M | $-9.11M |
| EPS | — | — | — | — | $-0.43 |
| Free cash flow | $-31.06M | $-32.97M | $-41.77M | $-23.88M | $-2.44M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-31 | UIHLEIN, RICHARD E | Buy | 31,825,235 | $3.00 |
| 2026-07-31 | UIHLEIN, RICHARD E | Buy | 2,550,932 | $4.05 |
| 2026-07-14 | JAMIL, KHURRAM | Sale | 16,250 | — |
Peer comparison
Smart narrative
Galectin Therapeutics Inc trades at $3.93. Our Smart Value Score of 19/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -34.27, it sits in the distress.
Frequently asked questions
What is Galectin Therapeutics Inc's stock price?
Galectin Therapeutics Inc (GALT) trades at $3.93.
Is Galectin Therapeutics Inc overvalued?
Galectin Therapeutics Inc carries a Smart Value Score of 19/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Galectin Therapeutics Inc (GALT)?
The 12-month analyst consensus target is $11.00, about 179.9% above the current $3.93. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Galectin Therapeutics Inc's Altman Z-Score is -34.27, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-3,728.00%
Beta0.39
50D MA$3.72
200D MA$3.33
Shares out0.10B
Float0.05B
Short ratio—
Avg volume0.3M
Performance
1 week-15.18%
1 month+10.76%
3 months+46.44%
YTD-6.01%
1 year—
3 years—
5 years—